Alina Tanase

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10881221/publications.pdf

Version: 2024-02-01

1040056 996975 16 254 9 15 citations h-index g-index papers 17 17 17 358 citing authors all docs docs citations times ranked

#	Article	lF	CITATIONS
1	Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. International Journal of Nanomedicine, 2016, 11, 641.	6.7	34
2	Approach to the Adult Acute Lymphoblastic Leukemia Patient. Journal of Clinical Medicine, 2019, 8, 1175.	2.4	28
3	Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 501-515.	6.1	27
4	A narrative review of central nervous system involvement in acute leukemias. Annals of Translational Medicine, 2021, 9, 68-68.	1.7	25
5	MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. Annals of Hematology, 2015, 94, 1081-1092.	1.8	22
6	LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Frontiers in Oncology, 2019, 9, 892.	2.8	20
7	Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?., 2020, 8, e000742.		15
8	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 329-345.	6.1	14
9	Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician. Journal of Clinical Medicine, 2019, 8, 884.	2.4	14
10	Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease?. Acta Haematologica, 2016, 135, 211-216.	1.4	10
11	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis. Journal of Cellular Physiology, 2018, 233, 422-433.	4.1	9
12	Periodontal disease might be a risk factor for graft versus host disease. A systematic review. Critical Reviews in Oncology/Hematology, 2020, 147, 102878.	4.4	9
13	Protein dysregulation in graft versus host disease. Oncotarget, 2018, 9, 1483-1491.	1.8	9
14	Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2019, 10, 2856.	4.8	8
15	Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. A case report. Medical Ultrasonography, 2017, 19, 330.	0.8	7
16	Transthoracic ultrasonography for the immunocompromised patient. A pilot project that introduces transthoracic ultrasonography for the follow-up of hematological patients in Romania. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2017, 55, 103-116.	0.6	3